BMJ case report links refractory nausea to unverified retatrutide injections

The wire

1. 01BMJ Case Reports describes five days of persistent nausea, vomiting, loose stools and reduced oral intake that did not respond to intravenous fluids, metoclopramide, ondansetron or domperidone; a Naranjo score of 7 indicated probable causality.
2. 02Blood tests, urinalysis, abdominal ultrasound and cerebral MRI found no alternative cause, and the patient did not consider the injections to be medication, so the exposure surfaced only on repeated non-judgemental questioning.
3. 03Symptoms improved two days after admission and resolved within a week; the product was never verified to contain retatrutide, and the authors urge clinicians to ask explicitly about peptides, research chemicals and wellness-practitioner injections.

From the source

Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide

BMJ case reports · 2026 Oct 7 · Buzzi RM, Huber LC et al.